The Center for Immuno-Oncology (CIO) investigates how our immune system reacts to cancer and what we can do to improve tumour immunity. We combine deep fundmental understanding of immunology with preclinical studies to translate new knowledge into clinical trials with the aim of developing new life-saving treatments for a spectrum of cancers.
Oxford’s long history of excellence in immunology is now focused on cancer, and CIO is the hub of the University-wide Oxford Cancer Immuno-Oncology Network (OCION) which links immuno-oncology researchers from multiple disciplines from across the University of Oxford, its affiliated hospitals and industrial partners.
What's new for Oxford Cancer
-
New Study Finds Common Virus May Improve Skin Cancer Treatment Outcomes
23 April 2025
-
New vaccines that aim to prevent cancer: Starting the conversation
14 April 2025
-
CRUK funding for research into earlier detection of relapse in people with multiple myeloma
9 April 2025
-
£5.5m Research Funding to Transform Bowel Cancer Care
31 March 2025
-
Project submissions welcome for the DPhil in Cancer Science
28 March 2025
CIO News
Oxford Immunology Symposium 2025
3 February 2025
The BSI Oxford Immunology Group, in collaboration with the University of Oxford Immunology Network, is pleased to present a one-day showcase of the fantastic immunology research happening across Oxford.
Agonists and Antagonists in Combined Immunotherapies for Cancer
3 February 2025
Prof. Nacho Melero delivers a talk on Immunotherapies in Cancer for GLOBAL IMMUNOTALKS
Reversing resistance to cancer immune therapy with antibodies
30 January 2025
A new study led by Professor Ignacio Melero of NDM's Centre for Immuno-oncology and the University of Navarra and has highlighted a way to combat resistance to cancer immunotherapy in solid tumours by using antibodies that target GDF-15 protein.
Dr Lennard Lee featured in Fujifilm anniversary documentary series
30 January 2025
CIO Dr Lennard Lee has been featured in Fujifilm Europe’s 90th Anniversary celebration documentary series, which honours 20 exceptional innovators helping to shape the future across Europe. Dr Lee has been recognised as a UK exemplar for his groundbreaking contributions to the cancer vaccines research field demonstrating a faster, simpler, and more efficient model for clinical trials.
Latest publications
-
Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse
Heras-Murillo I. et al, (2025), Nature Communications, 16
-
A phase I dose escalation and cohort expansion study of CB307, a trispecific Humabody® against PSMA, CD137, and albumin in patients with PSMA-positive solid tumors.
de Bono JS. et al, (2025), Clinical cancer research : an official journal of the American Association for Cancer Research
-
Recurrent ERBB2 alterations are associated with esophageal adenocarcinoma brain metastases.
Lawson NM. et al, (2025)
-
Figure 2 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Diers AR. et al, (2025)
-
Supplementary Figure S1 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Diers AR. et al, (2025)
-
Supplemental Figure 4 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Diers AR. et al, (2025)
-
Supplemental Figure 3 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Diers AR. et al, (2025)
-
Supplemental Figure 2 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Diers AR. et al, (2025)
-
Data from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Diers AR. et al, (2025)
-
Figure 6 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Diers AR. et al, (2025)
-
Supplemental Figure 5 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Diers AR. et al, (2025)
-
Figure 1 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Diers AR. et al, (2025)
-
Figure 4 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Diers AR. et al, (2025)
-
Figure 5 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Diers AR. et al, (2025)
-
Figure 3 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Diers AR. et al, (2025)
Oxford Talks
-
Thursday, 01 May 2025, 10am to 11.30am
Speakers: Matthew Neely, Jeremy McIlwaine, Lucy McCann
Venue: Weston Library, Broad Street OX1 3BG
-
Thursday, 01 May 2025, 10am to 12pm
Venue: Pembroke College, St Aldates OX1 1DW
-
Thursday, 01 May 2025, 11am to 12pm
Speakers: Dr Hannah Long
Venue: NDM Building, Headington OX3 7FZ
-
Thursday, 01 May 2025, 11am to 12.30pm
Speakers: Zack Paikin, Trita Parsi, Louise Fawcett
Venue: St Antony's College - North Site
-
Thursday, 01 May 2025, 12pm to 1pm
Speakers: Professor Adrian Liston
Venue: MRC Weatherall Institute of Molecular Medicine, Headington OX3 9DS